Paradigm Biopharmaceuticals Limited (PBIGF) Research

Melbourne, Australia-based Paradigm Biopharmaceuticals Limited operates as a drug repurposing company, focusing on the discovery and development of therapeutic products for human application. The company's core offering is an injectable formulation of pentosan polysulfate sodium (PPS), which is being developed to address various medical conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, Chikungunya virus, and acute respiratory distress syndrome. The company was established in 2014.

Market snapshot

Symbol
PBIGF
Price
$0.18
Day change
+5.85%
Market cap
$73.7M
P/E ratio
-1.95x
52-week range
0.10086-0.3468
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Nuo Therapeutics, Inc. (AURX)
  • Imugene Limited (IUGNF)
  • Kintor Pharmaceutical Limited (KNTPF)
  • Satellos Bioscience Inc. (MSCLF)
  • Orexo AB (publ) (ORXOF)
  • Pacific Edge Limited (PFGTF)
  • Poolbeg Pharma PLC (POLBF)
  • Shield Therapeutics plc (SHIEF)

Open Paradigm Biopharmaceuticals Limited (PBIGF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.